Skip to main content
. 2020 Nov 2;2(2):fcaa183. doi: 10.1093/braincomms/fcaa183

Figure 5.

Figure 5

Median change in seizure frequency throughout the proof-of-concept trial. Treatment with PSL was associated with a rapid and sharp decline in seizure frequency within a week of initiation. No loss of efficacy was observed over the 8-week maintenance period.